Hormone Replacement After Breast Cancer: Is It Safe?

被引：5
作者：
Liotta, Margaret [1 ]
Escobar, Pedro F. [1 ]
机构：
[1] Cleveland Clin, Div Gynecol Oncol, Dept Obstet & Gynecol, Cleveland, OH 44106 USA
来源：
CLINICAL OBSTETRICS AND GYNECOLOGY | 2011年 / 54卷 / 01期
关键词：
hormone therapy; breast cancer risk; estrogen; MENOPAUSAL SYMPTOMS; HOT FLUSHES; THERAPY; MANAGEMENT; VENLAFAXINE; TAMOXIFEN; FLASHES; TRIAL; WOMEN; RISK;
D O I：
10.1097/GRF.0b013e3182083cbb
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
The use of hormone therapy for climacteric symptoms in patients with breast cancer has become a significant and important point of discussion due in part to the improved survival from this disease in recent years. There is a theoretic risk that exogenous hormones will stimulate the growth of microscopic disease and lead to decreased survival and increased recurrence. In addition, 2 large studies have shown that there is an association between hormone therapy and breast cancer risk in women without an earlier history of breast cancer. Other studies suggest that estrogen alone may have a superior safety profile than estrogen and progesterone in combination. Hormone therapy could be justified for improvement of quality of life when other options have failed and the patient is informed of the risks.
引用
收藏
页码：173 / 179
页数：7
相关论文
共 20 条
[11]   Increased risk of recurrence after hormone replacement therapy in breast cancer survivors [J].
Holmberg, Lars ;
Iversen, Ole-Erik ;
Rudenstam, Carl Magnus ;
Hammar, Mats ;
Kumpulainen, Eero ;
Jaskiewicz, Janusz ;
Jassem, Jacek ;
Dobaczewska, Daria ;
Fjosne, Hans E. ;
Peralta, Octavio ;
Arriagada, Rodrigo ;
Holmqvist, Marit ;
Maenpa, Johanna .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (07) :475-482
[12]   Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women [J].
Hulley, S ;
Grady, D ;
Bush, T ;
Furberg, C ;
Herrington, D ;
Riggs, B ;
Vittinghoff, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (07) :605-613
[13]  
Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI [10.3322/caac.20006, 10.3322/caac.21387]
[14]   Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial [J].
Kenemans, Peter ;
Bundred, Nigel J. ;
Foidart, Jean-Michel ;
Kubista, Ernst ;
von Schoultz, Bo ;
Sismondi, Piero ;
Vassilopoulou-Sellin, Rena ;
Yip, Cheng Har ;
Egberts, Jon ;
Mol-Arts, Mirjam ;
Mulder, Roel ;
van Os, Steve ;
Beckmann, Matthias W. .
LANCET ONCOLOGY, 2009, 10 (02) :135-146
[15]   What can be done about hot flushes after treatment for breast cancer? [J].
Kontos, M. ;
Agbaje, O. F. ;
Rymer, J. ;
Fentiman, I. S. .
CLIMACTERIC, 2010, 13 (01) :4-21
[16]   Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial [J].
Loprinzi, CL ;
Kugler, JW ;
Sloan, JA ;
Mailliard, JA ;
LaVasseur, BI ;
Barton, DL ;
Novotny, PJ ;
Dakhil, SR ;
Rodger, K ;
Rummans, TA ;
Christensen, BJ .
LANCET, 2000, 356 (9247) :2059-2063
[17]   Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible? [J].
Marsden, J ;
Whitehead, M ;
A'Hern, R ;
Baum, M ;
Sacks, N .
FERTILITY AND STERILITY, 2000, 73 (02) :292-299
[18]   Risks and benefits of estrogen plus progestin in healthy postmenopausal women - Principal results from the Women's Health Initiative randomized controlled trial [J].
Rossouw, JE ;
Anderson, GL ;
Prentice, RL ;
LaCroix, AZ ;
Kooperberg, C ;
Stefanick, ML ;
Jackson, RD ;
Beresford, SAA ;
Howard, BV ;
Johnson, KC ;
Kotchen, JM ;
Ockene, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (03) :321-333
[19]   Tamoxifen for breast cancer among hysterectomised women [J].
Veronesi, U ;
Maisonneuve, P ;
Sacchini, V ;
Rotmensz, N ;
Boyle, P .
LANCET, 2002, 359 (9312) :1122-1124
[20]   Menopausal hormone therapy after breast cancer: The Stockholm randomized trial [J].
von Schoultz, E ;
Rutqvist, LE .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (07) :533-535
12